IMHO,  i think that Friday's closing price of $1.81 was priced into the expectation of a failed primary endpoint  plus the few hints of postives data of the sub analysis and Secondary endpoints that DM showed us via the forest plot at the AGM.  For me the Kidney Data was very impressive as well as most of the sub analysis data that as investors had yet seen and hopefully will be enough for a major BP after years of discussions that now they are able pull the trigger and lock up this novel technology at a reduced price since the primary endpoint was missed or underpowered. As suggested i could see a BP with an upfront payment or CVR deal so reduce their risk if the science does not pan out yet they get all the IP and the tax loss savings,  I think that would be a win win for both parties.  I look at Amarin marketcap of 8 billion USD and i see RVX market cap at $300 million USD,  RVX MACE data of 21 % RRR was not that far off as Amarin 25% RRR yet we are priced in  at 5% their valuation.  There is a disconnect in valuation iMO. If we had a partner that valuation would change.  I hope DM either spills the beans or gives us details of a potentional partner or maybe it will be revealed.... who knows